Saturday 17 October 2026
Export ONCO’s income statement to Excel — free account
Onconetix, Inc.
ONCO Healthcare Biotechnology
Onconetix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $815,400.00, down 67.7% from fiscal 2024. In the quarter to June 2026, revenue fell 83.9%, EPS grew 99.5% and free cash flow fell 36.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.48
0.07
−12.73%
Follow ONCO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 1.31 | 0.00 |
P/S ratio |
3.57 | 1.80 | 1.27 | 3.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.37) | (0.47) | (0.44) | (1.32) | |
P/B ratio |
1.30 | 0.09 | 0.08 | 0.19 | |
Price to Tangible BV |
0.00 | 0.00 | 0.61 | 0.66 | |
EV/Sales |
2.98 | (4.46) | (3.62) | (5.09) | |
EV/EBITDA |
0.00 | 0.21 | 0.17 | 0.20 | |
EV/Operating CF |
(0.49) | 0.38 | 0.27 | 0.32 | |
EV/FCF |
(0.48) | 0.37 | 0.27 | 0.32 | |
Quick Ratio |
0.05 | 0.61 | 1.23 | 2.02 | |
Current Ratio |
0.08 | 0.66 | 1.41 | 2.21 | |
Net Debt/EBITDA |
0.43 | 4.10 | 0.36 | 2.18 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.03 | 0.04 | 0.04 | |
Operating CF/Net income |
0.36 | (0.55) | 0.50 | 0.67 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(6.89) | (305.10) | (4,648.09) | (620.64) | |
Research and Development Expense of Revenue |
(1.05%) | 8.00% | 236.28% | 19.88% | |
Selling, General and Administrative Expense of Revenue |
770.93% | 495.65% | 9,485.12% | 13,132.75% | |
Intangible Assets out of Total Assets |
0.92 | 0.74 | 0.69 | 0.59 | |
Share Based Compensation of Revenue |
3.23% | 1.42% | 103.72% | 43.27% | |
Graham Net Nets |
(3.43) | (2.11) | 1.33 | 1.40 | |
Graham Number |
17,509.28 | 0.00 | 218.86 | 183.10 | |
Earnings Yield |
72,974.69% | (2,778.54%) | 76.51% | 21,957.52% | |
Free Cash Flow Yield |
(172.42%) | (661.95%) | (1,048.72%) | (407.85%) | |
Revenue per Share |
10.81 | 16.15 | 0.34 | 0.01 | |
Operating CF per Share |
(113.09) | (164.39) | (33.73) | (0.86) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(113.09) | (164.39) | (33.73) | (0.86) | |
Cash per Share |
29.77 | 277.70 | 59.08 | 2.65 | |
Shareholders Equity per Share |
120.07 | 838.54 | 186.75 | 6.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
120.07 | 838.54 | 186.75 | 6.01 | |
Free Cash Flow |
(3.18) | (3.09) | (2.12) | (1.92) | |
Working Capital |
(15.00) | (3.07) | 1.26 | 3.57 | |
Net Current Asset Value |
(15.00) | (3.10) | 1.24 | 3.56 | |
EV/EBIT |
0.00 | 0.20 | 0.17 | 0.20 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.05 | 0.19 | 0.03 | 0.01 | |
Average Payables |
2.96 | 2.77 | 2.06 | 2.21 | |
Average Inventory |
0.14 | 0.11 | 0.15 | 0.18 | |
Average Assets |
40.80 | 26.55 | 16.80 | 17.77 | |
Average Common Equity |
22.20 | 12.15 | 7.87 | 9.69 |
Columns are period end dates